Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White to off-white solid
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (20 mg/ml). Slightly ethanol.
Downloads
- Safety Data Sheet
- CDX C0755 MSDS.pdf
Category: Building Blocks, Intermediates, Reagents
Cabozantinib is a potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of endothelial growth factor receptor 2 (VEGFR2) (IC50=0.035nM), the hepatocyte growth factor receptor c-Met (IC50=1.3nM), AXL (IC50=7nM), fms like tyrosine kinase 3 (FLT3) (IC50=11.3nM), mast/stem cell growth factor (KIT) (IC50=4.6nM), RET (IC50=5.2nM), tyrosine-protein kinase receptor (TIE-2) (IC50=14.3nM) and RON (IC50=124nM). Cabozantinib reduces cell proliferation and vascular density. It also induces apoptosis and intratumoral hypoxia. Cabozantinib exhibits dose-related tumor growth inhibition, tumor regression, angiogenesis and/or metastasis inhibition in a broad range of preclinical tumor models. The anticancer compound cabozantinib has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and glioblastoma.
Synonyms | BMS-907351, XL184 |
---|---|
Purity | ≥98% (HPLC) |
Appearance | White to off-white solid |
CAS-Number | 849217-68-1 |
Molecular Formula | C28H24FN3O5 |
Molecular Weight | 501.5 |
Identity | 1H-NMR |
Solvents | DMSO (20 mg/ml). Slightly ethanol. |
Smiles | O=C(NC1=CC=C(OC2=C3C=C(C(OC)=CC3=NC=C2)OC)C=C1)C4(C(NC5=CC=C(C=C5)F)=O)CC4 |
InChi Key | ONIQOQHATWINJY-UHFFFAOYSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Transportation | Not dangerous goods |
References | (1) Y. Zhang, et al., IDrugs 13, 112 (2010), (2) R. Kurzrock, et al., J. Clin. Oncol. 29, 2660 (2011), (3) F.M. Yakes, et al., Mol. Canc. Ther. 10, 2298 (2011), (4) S. Roy, et al., Anticancer Agents Med. Chem. 15, 37 (2015) (Review), (5) N.M. Tannir, et al., Curr. Oncol. Rep. 19, 14 (2017) (Review), (6) C. Grullich, Recent Res. Cancer Res. 211, 67 (2018) (Review), (7) J.N. Markowitz & K.M. Fancher,, Pharmacotherapy 38, 357 (2018) (Review), (8) A. Desai & E.J. Small, Future Oncol. 15, 2337 (2019) (Review), (9) J. Trojan, Drugs 80, 1203 (2020) (Review) |
InChi | InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34) |
Quantity | 10 mg, 50 mg, Bulk |